Notably, a clinical trial (NCT02752035) is currently evaluating the combination of gilteritinib and azacitidine in 183 patients with newly diagnosed FLT3-mutated AML who are ineligible for intensive induction chemotherapy, with promising results showing significantly higher composite CR rates
Because of this targeted structure, it is discussed in research in the context of fat metabolism rather than the broader effects of full growth hormone
We have been successfully using GIPs and GLP-1s for years at our clinic in conjunction with our metabolic health program focusing on hormone health, food, sleep, and exercise
An interaction between MAPKs, neuroinflammation, and oxidative stress is well-established
Whenever youre activating something in the brain, we can expect that the brain and the GI tract may respond with nausea. GLP-1 medications also work in the gut by slowing down the digestion process, so food is in the stomach for a longer period of time